|
|
|
|
| LEADER |
01060 am a22002053u 4500 |
| 001 |
125165 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a Boire, Adrienne
|e author
|
| 100 |
1 |
0 |
|a Koch Institute for Integrative Cancer Research at MIT
|e contributor
|
| 700 |
1 |
0 |
|a Coffelt, Seth B.
|e author
|
| 700 |
1 |
0 |
|a Quezada, Sergio A.
|e author
|
| 700 |
1 |
0 |
|a Vander Heiden, Matthew G.
|e author
|
| 700 |
1 |
0 |
|a Weeraratna, Ashani T.
|e author
|
| 245 |
0 |
0 |
|a Tumour Dormancy and Reawakening: Opportunities and Challenges
|
| 260 |
|
|
|b Elsevier BV,
|c 2020-05-11T20:43:53Z.
|
| 856 |
|
|
|z Get fulltext
|u https://hdl.handle.net/1721.1/125165
|
| 520 |
|
|
|a Tumour dormancy presents challenges for clinical control and opportunities for scientific discovery. Current pictures of the mechanisms of tumour dormancy and reawakening remain incomplete. The Cancer Research UK's third Marshall Symposium explored tumour dormancy and reawakening in all their forms. In this forum article, we highlight the key challenges and opportunities discussed at this symposium.
|
| 546 |
|
|
|a en
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Trends in Cancer
|
